clinical trial · NCT04964986
Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)
VectivBio AG·phase2·completed·n = 10
Short Bowel SyndromeApraglutide
brief summary
The primary objective of the trial is to evaluate the safety of apraglutide in adult subjects with SBS-IF and CIC.
started
Jun 14, 2021
primary completion
Jun 6, 2023
completion
Jun 6, 2023
last updated
Jun 18, 2025
detailed description
This is an international, multicenter trial to evaluate the safety of apraglutide in adult participants with SBS-IF and CIC. The active pharmaceutical ingredient is apraglutide, an investigational glucagon-like peptide-2 (GLP-2) analogue. The trial consists of an evaluation period of 52 weeks.
official title
A Multicenter, Open-label, Metabolic Balance Study to Evaluate the Effects of Apraglutide on Intestinal Absorption in Adult Subjects With Short Bowel Syndrome, Intestinal Failure (SBS-IF), and Colon-in-Continuity (CIC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol